April 13, 2018
Patients with type 1 diabetes often have sub-optimal glycemic control. The gold standard of treatment is basal-bolus insulin or continuous subcutaneous insulin infusion via an insulin pump. However, only a third of patients with type 1 diabetes achieve the American Diabetes Association A1C goal <7%. There has been particular interest in using SGLT-2 inhibitors in patients with type 1 diabetes due to their ability to decrease body weight and blood pressure as well as improve glycemic control and perhaps cardiovascular outcomes. InTandem3 was a phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of sotagliflozin, a novel dual SGLT 1 and 2 inhibitor, in patients with Type 1 diabetes.
Guest Author: Diana Isaacs, Pharm.D., BCPS, BD-ADM, CDE
Music by Good Talk
January 13, 2017
Pharmacotherapy for diabetes management has expanded in recent years with several new drug classes. Current guidelines recommend several options for patients who have not reached their goal A1c on metformin monotherapy including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or basal insulin. However, if basal insulin is chosen as the first add-on treatment with metformin, the post-prandial blood glucose (PPG) often will remain elevated. A combination product that includes both a basal insulin plus a GLP-1 RA has the potential to addresses both fasting blood glucose and PPG … and perhaps has some other advantages over using either product alone.
Theme Music by Good Talk
March 11, 2016
Basal, prandial, NPH, ultra-long, inhaled, 70/30, 75/25,
50/50, U-100, U-200, U-300, and U-500 insulin … the list of options for
patients with diabetes requiring insulin continues to expand. Current
guidelines for glycemic management of patients with type 2 diabetes provide
specific recommendations for the initiation of insulin therapy, but not insulin intensification. The recently published LanScape study provides a foundation for making evidence-based
July 10, 2015
The American Diabetes Association and European Association for the Study of Diabetes (ADA/EASD) guidelines acknowledge that “CSII is a less commonly used and more costly alternative” to basal-bolus therapy in patients with T2DM. The Opt2mise was a robust study intended to clarify the role of CSII in patients with T2DM.